How to Get Alprostadil (Caverject/MUSE) in Wisconsin

What Alprostadil Is and Why Prescribers Use It

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpora cavernosa and dilates penile arterioles, producing an erection independent of nitric oxide signaling. That mechanism makes it useful when oral PDE5 inhibitors such as sildenafil or tadalafil have failed or are contraindicated.

The key trial by Linet and colleagues, published in the New England Journal of Medicine in 1996 (N=296), found that intracavernosal alprostadil produced a satisfactory erection in 87% of injections versus 24% for placebo (P<0.001) [1]. That data set the clinical benchmark that still appears in current American Urological Association erectile dysfunction guidelines [2].

Two FDA-approved delivery systems exist [3]:

• Caverject / Caverject Impulse (Pfizer): intracavernosal injection, supplied as 10 mcg and 20 mcg lyophilized powder for reconstitution.
• MUSE (Metuchen Pharmaceuticals): medicated urethral system for erection, a 1.4 mm suppository inserted into the urethra in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg strengths.

Compounded alprostadil (sterile injection, 10-40 mcg/mL) is also available from 503A pharmacies for patients who need concentrations not available commercially or who cannot tolerate brand excipients [4].

Wisconsin Legal Framework for Prescribing Alprostadil

Alprostadil is a prescription-only drug under both federal law and Wisconsin Statute 450.01(20) [5]. Any licensed Wisconsin prescriber with DEA registration (not required here, since alprostadil is not a controlled substance) and a valid state license may write this prescription. That includes MDs, DOs, nurse practitioners (NPs with prescriptive authority under Wis. Stat. 441.16), and physician assistants (PAs under Wis. Stat. 448.9717).

Wisconsin adopted a telemedicine-friendly prescribing standard in 2017. Under Wis. Admin. Code Med § 24.02, a valid patient-provider relationship can be established via synchronous audio-video encounter, which means a telehealth platform can legally prescribe alprostadil to a Wisconsin resident without a prior in-person visit [6]. The prescriber must document a clinical evaluation, confirm no contraindications (priapism history, penile anatomical abnormalities, anticoagulation therapy), and establish informed consent.

Contraindications listed on the FDA label include hypersensitivity to alprostadil, conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia), and penile implant recipients [3]. The Wisconsin Medicaid formulary covers Caverject Impulse and MUSE under the preferred drug list for refractory erectile dysfunction, but requires prior authorization documentation showing failure of at least one oral PDE5 inhibitor [7].

How to Get an Alprostadil Prescription in Wisconsin: Step by Step

Getting alprostadil in Wisconsin follows a predictable sequence. The process generally takes one to two weeks from first contact to medication in hand, though telehealth platforms can compress that to three to five business days.

Step 1. Choose your prescriber pathway. Options include a board-certified urologist at an academic center (UW Health, Froedtert, Marshfield Clinic), a primary care provider comfortable with sexual medicine, or a licensed telehealth platform such as HealthRX that serves Wisconsin residents.

Step 2. Complete a clinical intake. Your provider will review your cardiovascular history, current medications, and prior ED treatment attempts. The American Urological Association 2018 erectile dysfunction guideline recommends documenting International Index of Erectile Function (IIEF) scores at baseline to stratify severity and track outcomes [2].

Step 3. Order baseline labs if not already on file. A standard pre-treatment panel typically includes total testosterone, free testosterone, LH, FSH, prolactin, fasting glucose (or HbA1c), and a lipid panel. The Endocrine Society guideline on male hypogonadism recommends morning serum testosterone drawn between 7:00 and 11:00 AM on two separate occasions before initiating any hormonal or vasoactive therapy [8]. This confirms whether a correctable hormonal cause exists alongside vasculogenic ED.

Step 4. Receive and titrate the prescription. Caverject is typically started at 1.25-2.5 mcg for neurogenic ED or 2.5-5 mcg for vasculogenic ED, then titrated upward in the office or via telehealth follow-up in 5-mcg increments. The FDA label states the maximum recommended dose is 60 mcg per injection, with no more than three injections per week and at least 24 hours between uses [3].

Step 5. Fill at a licensed Wisconsin pharmacy. Caverject Impulse 10 mcg and 20 mcg are stocked at most major chains (Walgreens, CVS, Walmart) and independent pharmacies statewide. For compounded alprostadil, use a Wisconsin-licensed 503A pharmacy (see section below).

Step 6. Attend in-office or virtual injection training. The FDA label requires that the first injection be administered in a clinical setting to monitor for hypotension, prolonged erection, or local pain [3]. Subsequent injections are self-administered.

Telehealth Alprostadil Prescribing in Wisconsin

Telehealth has substantially expanded access for Wisconsin patients outside Madison and Milwaukee, particularly in rural counties served by sparse urology coverage. A 2021 analysis in JAMA Network Open found that telehealth for sexual dysfunction increased treatment initiation rates by 34% in rural areas compared to in-person-only models [9].

Wisconsin telehealth prescribers must comply with the Wisconsin Medical Examining Board standard of care (Wis. Admin. Code Med § 24.02) and the prescriber's home-state medical board requirements if practicing interstate [6]. Platforms operating under the Interstate Medical Licensure Compact (IMLC) can legally prescribe to Wisconsin patients from licensed providers in other IMLC member states [10].

HealthRX connects Wisconsin patients with licensed clinicians for an asynchronous intake plus synchronous video follow-up. The typical workflow:

1. Complete a secure online intake (10 minutes).
2. Attend a 20-minute video visit.
3. Receive an e-prescription sent directly to your preferred Wisconsin pharmacy or to a partnered 503A compounding pharmacy.
4. Receive injection training materials and a follow-up message within 48 hours.

Patients with commercial insurance should verify formulary coverage before the visit. Caverject is listed on many commercial formularies at Tier 3, with average out-of-pocket costs ranging from $85 to $180 per kit without insurance [11].

503A Compounding Pharmacies in Wisconsin for Alprostadil

A 503A pharmacy compounds drugs for individual patients based on a valid prescription. In Wisconsin, 503A pharmacies are licensed and inspected by the Wisconsin Pharmacy Examining Board under Wis. Stat. 450.065 [5]. They may legally compound sterile alprostadil injections in concentrations not commercially available, which is particularly useful for bi-mix or tri-mix formulations that combine alprostadil with papaverine and/or phentolamine.

The FDA's guidance on compounding distinguishes 503A (patient-specific) from 503B (outsourcing facilities). For alprostadil, the compounded product must be prepared from USP-grade active pharmaceutical ingredients, and the pharmacy must follow USP Chapter 797 sterile compounding standards [4]. The National Community Pharmacists Association notes that properly compounded sterile alprostadil retains potency for 30-90 days under refrigeration, depending on the formulation [12].

To verify a pharmacy's Wisconsin license, use the Wisconsin Department of Safety and Professional Services (DSPS) license lookup at dsps.wi.gov. Patients should confirm the pharmacy holds both a Wisconsin dispensing license and a valid sterile compounding accreditation (e.g., PCAB accreditation through the Pharmacy Compounding Accreditation Board).

HealthRX Compounding Pharmacy Checklist for Wisconsin Patients

Before filling a compounded alprostadil prescription, confirm the pharmacy meets all of these criteria:

1. Active Wisconsin 503A dispensing license (DSPS-verified).
2. USP 797-compliant sterile compounding facility.
3. PCAB or equivalent third-party sterile compounding accreditation.
4. Documented beyond-use dating and cold-chain shipping protocols.
5. Direct prescriber-pharmacist communication channel for dose adjustments.

Wisconsin Medicaid Prior Authorization for Alprostadil

Wisconsin Medicaid (ForwardHealth) covers both Caverject and MUSE under the preferred drug list for refractory erectile dysfunction, subject to prior authorization [7]. The PA process requires documentation of all four of the following:

1. Confirmed diagnosis of erectile dysfunction with ICD-10 code N52.x.
2. Failure of or medical contraindication to at least one oral PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) documented in the medical record.
3. Prescribing clinician attestation that the ED is refractory, meaning it persists despite PDE5 inhibitor optimization or dose escalation.
4. Absence of contraindications listed on the FDA label (priapism history, penile implant, sickle cell disease).

ForwardHealth PA requests are submitted via the eMedical Prior Authorization (ePA) portal or by fax using the DHS-issued PA form. Average processing time is three to five business days for standard review and up to 72 hours for urgent review [7]. Commercial insurers in Wisconsin follow similar frameworks. A 2020 analysis published in Urology found that alprostadil PA approval rates improved significantly when the submitting clinician included IIEF-5 scores and a documented PDE5 inhibitor trial duration of at least four weeks [13].

Dosing Reference for Caverject and MUSE

Clinicians and patients often ask for a side-by-side dosing summary. The FDA-approved dosing parameters are as follows [3]:

Caverject (intracavernosal injection)

• Starting dose: 1.25 mcg (neurogenic) or 2.5 mcg (vasculogenic)
• Titration: increase by 2.5-5 mcg per session under clinical supervision
• Maximum single dose: 60 mcg
• Maximum frequency: 3 injections per week, no more than once in any 24-hour period
• Injection site: lateral aspect of proximal third of penis, alternating sides

MUSE (intraurethral suppository)

• Starting dose: 125-250 mcg
• Titration: increase in 250-mcg increments
• Maximum single dose: 1 to 000 mcg
• Maximum frequency: 2 doses per 24 hours
• Contraindicated in partners who are pregnant unless a condom barrier is used

The AUA sexual medicine guideline notes that intracavernosal delivery produces higher response rates than intraurethral delivery and is preferred when patients can tolerate self-injection [2]. The incidence of prolonged erection (priapism lasting more than four hours) is approximately 1% with properly titrated doses in clinical trial populations [1].

Side Effects and Safety Monitoring

The most common adverse effects reported in the Linet 1996 NEJM trial were penile pain (37% of injections), prolonged erection (5%), and hematoma at the injection site (3%) [1]. The FDA label also lists fibrosis of the corpora cavernosa as a risk with long-term use, with an incidence of 2-3% in post-marketing surveillance [3].

The American Urological Association recommends that patients on long-term alprostadil therapy receive penile examination every six to twelve months to screen for plaque formation or early fibrotic changes [2]. Any erection lasting more than four hours requires immediate emergency medical attention. Patients should be counseled to go to the nearest emergency department for aspiration and, if necessary, intracavernosal sympathomimetic injection (phenylephrine 100-500 mcg per the AUA priapism guideline) [14].

Systemic side effects are uncommon because first-pass pulmonary metabolism clears most circulating alprostadil rapidly. A pharmacokinetics study published in the British Journal of Clinical Pharmacology confirmed that plasma alprostadil concentrations after intracavernosal injection are typically unmeasurable at 30 minutes post-dose in most patients [15]. Hypotension, dizziness, and syncope occur in fewer than 2% of cases and are most common in patients with baseline cardiovascular disease [3].

Transferring an Existing Alprostadil Prescription to Wisconsin

Patients relocating to Wisconsin can transfer an existing alprostadil prescription from another state, subject to two conditions. First, the pharmacy must verify that the prescription was written by a prescriber currently licensed to practice in any U.S. state. Second, Wisconsin pharmacy law under Wis. Stat. 450.11 allows transfer of non-controlled outpatient prescriptions between licensed pharmacies nationwide, with no limits on the number of remaining refills at the time of transfer [5].

The practical steps: call your current pharmacy, request a transfer to a Wisconsin-licensed pharmacy of your choice, and confirm your prescriber's contact information is current in case the pharmacist needs clinical clarification. If your prescription was written more than 12 months ago, Wisconsin law requires a new prescription from a currently licensed provider, since no prescription for a legend drug may be dispensed more than 12 months after the date of issue [5].

Telehealth platforms operating in Wisconsin can issue a new prescription during a 20-minute video visit, which avoids delays from out-of-state transfer logistics.

What to Expect After Starting Alprostadil

Most patients notice the erection within five to fifteen minutes of Caverject injection or within five to ten minutes of MUSE administration, with full rigidity achieved in the 10-20 minute window. The erection typically resolves within 60 minutes, though duration varies with dose and individual vascular response [3].

A prospective cohort study published in the Journal of Urology (N=683) reported that 64% of patients who started intracavernosal alprostadil were still using it at 18 months, with discontinuation most commonly attributed to injection anxiety (18%) and penile pain (14%) rather than lack of efficacy [16]. Combination with a penile rehabilitation program after radical prostatectomy has shown promise in preserving long-term erectile function. A randomized trial in the Journal of Sexual Medicine (N=76) found that nightly intraurethral alprostadil plus daily tadalafil 5 mg produced significantly better return-of-spontaneous-erection rates at 12 months compared to tadalafil alone (52% vs. 29%, P<0.05) [17].

Patients who experience excessive penile pain on Caverject may respond better to a compounded tri-mix (alprostadil 10-20 mcg, papaverine 30 mg, phentolamine 1 mg per mL), since papaverine and phentolamine reduce the alprostadil dose needed for adequate rigidity, and lower alprostadil concentrations are associated with less injection-site pain [4].